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Background: Oral or enteral dietary supplementation with arginine, omega 3 fatty acids and nucleotides (known as
immunonutrition) significantly improve outcomes in patients undergoing elective surgery. The objective of the
study was to determine the impact on hospital costs of immunonutrition formulas used in patients undergoing
elective surgery for gastrointestinal cancer.
Methods: US hospital costs of stay with and without surgical infectious complications, and average cost per day in
the hospital for patients undergoing elective surgery for gastrointestinal cancer were estimated using data from the
Healthcare Cost and Utilization Project’s 2008 Nationwide Inpatient Sample. These costs were then used to estimate
the impact of perioperative immunonutrition on hospital costs using estimates of reduction in infectious
complications or length of stay from a meta-analysis of clinical trials in patients undergoing elective surgery
for gastrointestinal cancer. Sensitivity of the results to changes in baseline complication rates or length of stay
was tested.
Results: From the meta-analysis estimates, use of immunonutrition resulted in savings per patient of $3,300 with
costs based on reduction in infectious complication rates or $6,000 with costs based on length of hospital stay.
Cost savings per patient were present for baseline complication rates above 3.5% or when baseline length of stay
and infectious complication rates were reduced to reflect recent US data for those with upper and lower GI elective
cancer surgery (range, $1,200 to $6,300).
Conclusions: Use of immunonutrition for patients undergoing elective surgery for gastrointestinal cancer is an
effective and cost-saving intervention.Background
Infectious and other types of complications following
gastrointestinal cancer, head and neck cancer, and car-
diac surgery are frequent and add significantly to patient
morbidity as well as to hospital length of stay and costs
[1,2]. Published estimates of complication rates after sur-
gery for patients with gastrointestinal cancer, head and
neck cancer, and cardiac disease suggest that these rates
range between 15% and 54% [3-6]. Infectious complica-
tions include wound infections, abdominal abscess,
pneumonia, urinary tract infections, and sepsis. Other
types of complications include anastomotic leaks, acute
renal failure, and cardiovascular events. Complications* Correspondence: jmauskopf@rti.org
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reproduction in any medium, provided the orprolong the recovery period for the patient, require add-
itional days in the hospital, may increase mortality and
increase hospital costs [1].
Immunonutrition formulas composed of arginine,
omega-3 fatty acids, and nucleotides improve host
defenses, likely through the provision of key nutrients that
maintain T-lymphocyte and other immune functions [5,7].
Immunonutrition has been studied in multiple clinical
trials, consistently showing reduced postsurgical infectious
complications, and some studies also showing a decrease
in selected noninfectious complications in patients under-
going elective surgery, including patients undergoing
elective surgical interventions for gastrointestinal cancer.
Several meta-analyses have summarized the results of
these clinical trials, all demonstrating a 38%–62% risk re-
duction in infections and other complications [3-9]. Inral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lationship between hospital length of stay or postoperative
infectious complications or anastomotic leak, a noninfec-
tious complication, and the use of immunonutrition using
a nutritionally complete formula containing supraphysio-
logic quantities of arginine, omega-3 fatty acids, and
nucleotides (IMPACTW, Nestlé Science Health, Vevey,
Switzerland). The results of the Waitzberg meta-analysis
showed that, for all nutrition intervention strategies and
for all surgical patients studied, use of immunonutrition
resulted in lower postsurgical infectious complications, a
lower rate of anastomotic leak, and shorter length of stay.
In this paper we evaluated the impact on per-patient
hospital costs arising from the use of immunonutrition
perioperatively (both before and after surgery) in
patients undergoing elective surgery for gastrointestinal
(GI) cancer using the results from Waitzberg and collea-
gues [4] applying estimates of the cost of care of this pa-
tient population derived from the Healthcare Cost and




Table 1 presents the clinical outcome data used in
the study. Waitzberg and colleagues [4] identified 6Table 1 Perioperative immunonutrition support: clinical outco
Outcome variable With perioperative immun
N=442
Mean length of stay 13.31
Percentage reduction in length of stay
Percentage with any infectious complications 14.71%
Number (%) in pooled trial populations with
specific complicationsc
Wound infection 26 (5.9%)
Abdominal abscess 9 (2.0%)
Pneumonia 25 (5.7%)
Urinary tract infection 11 (2.5%)
Sepsis 8 (1.8%)
Anastomotic leak 15 (3.4%)
Abbreviations: Δ, absolute difference; RR relative risk with 95% confidence interval i
a Calculated from data reported in Waitzberg et al. [4].
b Three 240-mL (8-ounce) servings of oral supplement per day for five days prior to
goal of one liter per day.
c Note that a patient may experience more than one complication.perioperative studies in patients undergoing elective
upper or lower gastric surgery for gastrointestinal or
pancreatic cancer. Patients in the control groups in these
studies received enteral feeding with standard isocaloric,
isonitrogenous formulas. Patients in the treatment group
received IMPACT as immunonutrition support. From
each study, for the immunonutrition and control groups,
Waitzberg and colleagues [4] extracted data on hospital
length of stay and number and type of the following
postsurgical infectious complications: wound infection,
abdominal abscess, pneumonia, urinary tract infection,
and sepsis. Waitzberg and colleagues [4] also extracted
data on one noninfectious complication, anastomotic
leak. The difference in the mean length of stay and the
percentage of patients experiencing one of the abstracted
infectious complications in the control and immunonu-
trition groups were derived from the perioperative
immunonutrition support studies of GI surgery patients
presented in Waitzberg et al. [4].
Costing methodology
We used two methods to estimate the mean cost of a
hospital stay for each group. In the first costing method,
we estimated average cost of a hospital stay with infec-
tious complications and average cost of a hospital stay
without infectious complications for elective GI cancermesa




31.32% RR = 0.46
43 (9.6%) RR 0.61
(0.38, 0.96)
21 (4.7%) RR 0.43
(0.21, 0.91)
47 (10.5%) RR 0.54
(0.34, 0.87)
20 (4.5%) RR 0.53
(0.23, 1.19)
16 (3.6%) RR 0.53
(0.22, 1.27)
29 (6.5%) RR 0.52
(0.28, 0.95)
n ().
surgery, followed by early enteral feeding (within 24 hours postsurgery) at a
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then applied these estimated costs to the number of
patients with and without infectious complications in
the immunonutrition and control groups to estimate the
mean hospital cost per stay for each group. In the sec-
ond costing method, we multiplied the mean length of
stay for each group by the mean cost per day in hospital
for all elective GI cancer surgical patients in the 2008
HCUP NIS. The methods for estimating the hospital
cost per stay and hospital cost per day used in this ana-
lysis are described in detail below.Database description, conversion of charges to costs, and
identification of GI cancer surgery patients and
infectious complications
Nationally representative inpatient discharge data were
used to estimate hospital costs per stay and per day for
patients with a diagnosis of gastrointestinal cancer. Data
for this analysis were taken from the 2008 HCUP NIS, a
stratified sample of hospitals drawn from the subset of
hospitals in the United States (US) that make their data
available to HCUP [10,11]. The NIS is the largest, all-
payer inpatient care database in the US and contains
data from approximately eight million hospital stays in
2008. The database contains clinical and resource use
information typically included in discharge abstracts, in-
cluding patient demographics, International Class-
ification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) diagnosis and procedure codes, length of
stay, charges incurred, discharge status, admission type
and source, and hospital-specific characteristics. Survey
design elements provided with the NIS allow for generat-
ing nationally representative estimates. We converted
hospital charges to costs by applying facility-specific
cost-to-charge ratios, provided by HCUP, and then
adjusted all costs to 2010 US dollars using the medical
care component of the Consumer Price Index. All ana-
lyses were conducted using SAS statistical software
(SASW, Cary, North Carolina, US); survey procedures
(that is, PROC SURVEYMEANS and SURVEYREG) were
used to account for the complex survey design of the
NIS.
As the NIS contains information on the type of admis-
sion (e.g., emergency, urgent, elective) associated with
each unique hospital stay, we first identified all inpatient
stays that were classified as an elective admission. We
next identified stays with evidence of upper or lower
gastrointestinal cancer (all subcategories) using specific
ICD-9-CM diagnosis codes (150.xx, 151.xx, 152.xx, 153.
xx, 154.xx, 157.xx, 158.xx, and 159.xx) that also had
upper or lower gastrointestinal surgery as identified by
ICD-9-CM procedure codes 42.xx, 43.xx, 45.7x, 45.8, 46.
xx, 47.xx, 48.xx, 49.0, 49.1, 49.3 and 52.xx.ICD-9-CM diagnosis codes were used to identify those
patients who experienced one or more of the following
infectious complications: wound infection, ICD-9-CM
codes 031.xx (diseases due to other mycobacteria) and
039.xx-041.xx (actinomycotic infections, other bacterial
diseases, and bacterial infection in conditions classified
elsewhere); abdominal abscess, ICD-9-CM codes 567.22
(peritoneal abscess) and 998.59 (other postoperative in-
fection, abscess); pneumonia, ICD-9-CM codes 480.xx-
485.xx (viral pneumonia; pneumococcal pneumonia;
other bacterial pneumonia; pneumonia due to other spe-
cified organism; bronchopneumonia, organism unspeci-
fied; and pneumonia, organism unspecified); urinary
tract infection, ICD-9-CM code 599.0 (urinary tract in-
fection, unspecified/pyuria); sepsis and septicemia, ICD-
9-CM-codes 995.91 (systemic inflammatory response
syndrome due to infectious process without organ dys-
function) and 038.xx (infectious organisms in the blood-
stream); and anastomotic leak, ICD-9-CM code 997.4
(digestive system complications not elsewhere classified
including intestinal internal anastomosis and bypass).
Estimation of average cost per day in the hospital and
average cost per stay in the Hospital for those with and
without complications
To compute the average cost per day in the hospital for
the patient population of interest, the cost per stay was
divided by the length of stay for each patient, and the
mean average cost per day was computed for the patient
population of interest, those with an elective admission
for upper or lower gastrointestinal cancer surgery. For
the sensitivity analyses, average costs per day were also
estimated separately for those having upper GI cancer
surgery and for those having lower GI cancer surgery.
Patients having procedure codes for both upper and
lower GI cancer surgery were included in both analyses.
To compute the average cost per stay in the hospital
for those with and without complications, the 2008
HCUP NIS patients with elective surgery for GI cancer
were subdivided into either those with or without at
least one of the ICD-9-CM codes for infectious compli-
cations listed above or those with and without infectious
or other digestive complications including anastomosis
and bypass and the average cost per hospital stay esti-
mated for each population subgroup. These estimates
were also generated for the infectious complications sub-
groups for the upper GI and lower GI populations
separately.
Estimation of impact of immunonutrition formulas on
hospital costs
The cost savings per patient associated with nutrition
support with immunonutrition formulas were calculated
using two different methods: (1) multiplying the
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length of stay per patient by the average cost per day in
the hospital and (2) using the following formula to esti-
mate the mean hospital cost per patient for each treat-
ment group and computing the difference between the
groups: (cost per stay with no infectious complications ×
percentage with no infectious complications) + (cost per
stay with infectious complications × percentage with at
least one infectious complication). Both of these calcula-
tions allowed for a single patient to experience more
than one infectious complication.
Average selling prices for immunonutrition were
obtained from Nestlé HealthCare Nutrition. The costs
for perioperative immunonutrition were calculated as
follows: three servings of oral supplement for five days
before surgery at $29 per day and one liter of enteral for-
mula per day for seven days after surgery at $36 per day.
The cost of standard nutrition was not considered in the
analysis.
Sensitivity analyses
Two sensitivity analyses were performed. First, for the
combined upper and lower GI population, the infectious
complication rate for the control group was allowed to
vary from 0% to 40%, and the potential cost savings were
estimated. Second, since the average length of stay is dif-
ferent for upper and lower GI cancer surgery and length
of stay and infectious complication rates have been
declining in the US with the adoption of less invasive
surgical techniques, the potential cost savings wereTable 2 Estimated cost and length of stay with and without c
Input variable With complications (SD) Witho
Upper and lower GI combined, N = 95,198; Infectious Complication rate, 11.2%
Cost per day
Cost per stay $53,361 ($62,039) $20,40
Length of stay 18.24 (16.25) 7.43 (
Upper and Lower GI Combined, N = 95,198, Infectious +Other Complication Rate
Cost per day
Cost per stay $41,119 ($52,420) $19,62
Length of stay 14.81 (13.41) 7.02 (
Upper GI only, N = 11,291; Infectious Complication rate, 17.1%
Cost per day
Cost per stay $85,451 ($89,124) $34,19
Length of stay 25.03 (19.92) 10.11
Lower GI only, N = 83,974; Infectious Complication rate, 10.4%
Cost per day
Cost per stay $46,320 ($51,728) $18,69
Length of stay in days 16.75 (14.48) 7.09 (
Abbreviations: NIS Nationwide Inpatient Sample; GI gastrointestinal; HCUP Healthcar
a Costs in flated from 2008 dollars to 2010 using the medical care component of thestimated using, for the control population, infectious
complication rates and length of stay for the combined
population and the two populations separately estimated
from the 2008 HCUP NIS data rather than those from
trials included in the meta-analysis. For both of these
sensitivity analyses, Waitzberg and colleague’s [4] esti-
mates of the percentage reduction in the infectious com-
plication rate or length of stay of the control group
associated with the use of perioperative immunonutri-
tion was used to estimate the reduction in infectious
complication rate or length of stay for the groups re-
ceiving immunonutrition.
Institutional Review Board Consideration
RTI International’s Institutional Review Board (RTP, NC,
USA) determined that this study met all criteria for ex-
emption because only de-identified patient-level data or
aggregated patient data were used in the analysis.
Results
Results of the HCUP NIS analyses of costs are presented
in Table 2. The NIS data demonstrated that, for all
patients undergoing elective surgery for gastrointestinal
cancer in the US in 2008, the mean cost per stay for
patients presenting with infectious complications (or
presenting with infectious plus other complications) was
$53,361 ($41,119), whereas for those without infectious
complications (or without infectious plus other compli-
cations) it was $20.406 ($19,628). The average cost per
hospital day was $2,948. However, the average cost peromplications: results using 2008 HCUP NIS dataa
ut complications (SD) With or without complications (SD)
$2,948 ($2,642)




8 ($19,580) $24,096 ($30,838)
4.49) 8.64 (7.96)
$3,773 ($4,733)
4 ($37,964) $42,895 ($53,988)
(6.32) 12.65 (12.61)
$2,838 ($2,167)
7 ($17,764) $21,572 ($25,147)
4.42) 8.10 (6.93)
e Cost and Utilization Project; SD standard deviation.
e US Consumer Price Index.
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upper GI cancer surgery than for those undergoing
lower GI cancer surgery. Also presented in Table 2 is the
average length of stay for the populations of interest. Of
note are the lower average length of stay and infectious
complication rates for the combined upper and lower GI
cancer surgery patients than those observed in the clin-
ical trials reviewed by Waitzberg and colleagues [4].
When applying the HCUP NIS costs for hospital stays
with and without infectious complications for the com-
bined upper and lower GI population to the infectious
complication rates with and without immunonutrition
estimated in the Waitzberg meta-analysis, the mean cost
per stay was $26,402 per patient in the control group
and $22,743 per patient in the immunonutrition group,
leading to $3,300 (rounded to the nearest $100) saved
per patient due to immunonutrition use perioperatively
attributable to the reduced complication rate. Using the
estimated reduction in hospital length of stay of
2.18 days from Waitzberg’s meta-analysis gave an esti-
mated reduction in cost of $6,000 (rounded to the near-
est $100) per patient with immunonutrition when
compared with standard nutritional supplementation
(2.18*$2948)–$397. These results are presented in
Table 3.
The first sensitivity analysis aimed at determining the
baseline infectious complication rate at which cost sav-
ings from use of immunonutrition would offset the cost
of therapy. As illustrated in Figure 1, net cost savings
continued to be observed for infectious complication






Waitzberg et al. [4]. $6,000
ΔLOS= 2.18; ICR, 14.71% vs. 31.32%
Estimates using lower LOS and
infectious complication rates for
the control populationb
Upper + lower GI $3,200
ΔLOS= 1.21; ICR, 5.2% vs. 11.2%
Upper GI only $6,300
ΔLOS= 1.78; ICR, 7.9% vs.17.1%
Lower GI only $2,800
ΔLOS= 1.14; ICR, 4.8% vs. 10.4%
Abbreviations: Δ, absolute difference; GI gastrointestinal; HCUP Healthcare Cost and
immunonutrition vs. standard nutrition; LOS length of stay.
a Rounded to the nearest $100.
b Infectious complication rates and length of stay for the control population taken f
complications and percentage reduction in length of stay presented in Table 1 andIn the second sensitivity analysis, the infectious com-
plication rates, length of stay, and costs per day and per
stay with and without infectious complications were
taken from the 2008 HCUP NIS data analysis to show
the impact on cost savings for the combined population
as well as upper and lower GI cancer patients separately,
using more recent data on length of stay and infectious
complication rates. As presented in Table 3, the results
show that the cost savings are lower when using the in-
fectious complication rates and length of stay from the
total HCUP NIS GI cancer surgery population and the
lower GI cancer surgery population but higher for the
upper GI cancer surgery population because of the
higher hospital costs for the upper GI patients.
Discussion
Multiple studies (>20), including those studies per-
formed in patients undergoing elective surgery for
gastrointestinal cancers, support the use of immunonu-
trition as a low-risk strategy that effectively and signifi-
cantly decreases the risk of postsurgical complication in
patients undergoing major elective surgery [4,5]. The
analyses presented in this paper have demonstrated that
the use of perioperative (both before and after surgery)
immunonutrition also may be cost saving based on a
meta-analysis of available trials in GI cancer patients
using a single immunonutrition formula. Cost savings
with the use of immunonutrition have been previously
reported. However, the applicability of these studies has
been limited due to the fact that their analysis is done












Utilization Project; ICR infectious complication rate for perioperative
rom 2008 HCUP NIS values presented in Table 2 and relative risk of infectious










































Figure 1 Cost savings attributable to reduced infectious complications (presented in 2010 US dollars).
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database for different patient populations [14].
The estimated net cost savings was calculated through
two different approaches based on either a decrease in
infectious complication rate or in hospital length of stay
resulting from the use of immunonutrition. Interestingly,
even though a significant decrease in cost was evident
through either method, cost savings estimates based on
decrease in the infectious complication rate were lower
than estimates based on reduced hospital length of stay.
This suggests that immunonutrition may bring add-
itional benefits beyond reduction in risk of infectious
complications, including a reduced risk of noninfectious
complications (such as the reduction in anastomotic leak
shown in the Waitzberg and colleagues [4] meta-ana-
lysis), decreased severity of complications (such as a
more limited infection), or speedier recovery in patients
who do not develop complications. Indeed, some clinical
observations suggest that the use of immunonutrition
results in improved hemodynamics, including decreased
accumulation of lactate and base deficit, enhanced tissue
oxygenation, and improved T-lymphocyte function [15].
These physiologic benefits may translate into clinical
benefits that are difficult to quantify but nonetheless
may result in a shorter length of stay.
Our results using the incremental costs associated
with infectious complications were sensitive to the base-
line infectious complication rate, suggesting that cost
savings would decrease in patient populations or hospi-
tals with lower infectious complication rates. How-
ever, cost savings are estimated with the use of
immunonutrition when the infectious complication rate
is above 3.5%.
Our study has some limitations. First, noninfectious
complications were not included in the estimates that
were based solely on estimated reductions in infectious
complication rates, although the Waitzberg and collea-
gues [4] meta-analysis indicated a possible significant re-
duction in the noninfectious complication, anastomotic
leak (Table 1). However, the estimates based on hospital
length of stay would capture the effects of anyreductions in noninfectious complication. Second, the
studies included in the meta-analysis were completed
over 10 years ago, and surgical techniques and post-
operative management have evolved since then. Our
sensitivity analysis using the 2008 HCUP NIS data was
performed to assess the impact of more recent estimates
of infectious complication rates and hospital length of
stay in the US to address this limitation. Third, we used
results from a meta-analysis published in 2006. However,
more recent meta-analyses have estimated similar reduc-
tion in infectious complication rates and reductions in
hospital length of the stay for those taking immunonu-
trition perioperatively for gastrointestinal surgery [5-9].
For example, the Marimuthu and colleagues [9] meta-
analysis, which included data from several more recent
clinical trials, estimated a relative risk (RR) for infectious
complications of 0.53 and a reduction in hospital length
of stay of 2.71 days for those receiving immunonutri-
tion perioperatively. Their meta-analysis showed a lower
impact on length of stay when only preoperative immu-
nonutrition was provided (1.46 days), but a similar
impact on length of stay when only postoperative immu-
nonutrition was provided (2.44 days). Conversely, they
showed a greater impact on infectious complication
rates with only preoperative immunonutrition (RR =
0.48) and a lower impact with only postoperative
immunonutrition (RR = 0.68) than that estimated for
perioperative immunonutrition.
Conclusions
Our study, which used pooled data from multiple clin-
ical trials, demonstrates that a comparatively small in-
vestment in immunonutrition support both before and
after surgery for both upper and lower gastrointestinal
cancer surgery patients is likely to be more than offset
by the estimated savings due to reduced infectious com-
plications and/or hospital length of stay. Thus, the use
of immunonutrition support may be a valuable addition
to other strategies used by hospitals to control postsurgi-
cal infectious complications, improve patient outcomes,
and reduce hospital costs.
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